Disruption of SOX6 gene using CRISPR/Cas9 technology for gamma-globin reactivation: An approach towards gene therapy of beta-thalassemia

Abstract

Elevation of Hemoglobin F ameliorates symptoms of beta-thalassemia, a common autosomal recessive disorder. The transcription factor SOX6 plays a key role in the gamma to beta-globin gene switching. In the current investigation, a mutation was induced using the CRISPR/Cas9 technology in the binding domain region of SOX6 to reactivate gamma-globin expression. Three CRISPR/Cas9 cassettes were provided, whose single-guide RNAs targeted different regions in the SOX6 gene-binding domain. After transfection of K562 cells with CRISPR a, b and c, and subsequent erythroid differentiation, the indel percentage of the cells was about 30, 25, and 24, respectively. Relative quantification showed that the gamma-globin mRNA level increased to 1.3-, 2.1-, and 1.1-fold in the cells treated with CRISPR/Cas9 a, b, and c, respectively, compared with untreated cells. Our results show that mutation induction in the binding site of the SOX6 gene leads to gamma-globin reactivation. These findings support the idea that CRISPR interrupts the SOX6 binding site, and, as a result, SOX6 is incapable of binding the gamma-globin promoter. In conclusion, SOX6 disruption could be considered as a therapeutic approach for beta-thalassemia treatment. CRISPR/Cas9 was selected for this purpose as it is the most rapidly evolving technology.